Since serum levels of administered riluzole in patients are determined by the expression of CYP1A2,32 another way to increase the likelihood of response to riluzole could be to select ALS patients with low CYP1A2 levels. This evidence concerns the gene CYP1A2 and amyotrophic lateral sclerosis.